Matricel GmbH is a life sciences company which develops and produces innovative biomatrices, cell carrier and cell cultivation systems for applications in medicine and biotechnology. In addition, Matricel serves the medical community as a collagen supplying partner and cooperates in the development of collagen containing medical products with its proven development, manufacturing and regulatory expertise.

Matricel´s proprietary technologies in the area of collagen processing (purity, cell compatibility and safety), matrix production (control over pore structure and pore size), and cross-linking (control of the resorption time and degradation process) are the essential keys to successfully produce collagen-based, biocompatible and biodegradable matrices in a wide range of modifications suitable for the cultivation with human cells in tissue engineering and for further clinical applications in regenerative medicine.

Matricel´s collagen scaffold ACI-Maix^(TM) is one of the first products in Europe and Australia that was used clinically for the tissue engineering of articular cartilage. So far several thousand patients have been treated successfully with this product according to the so-called “Collagen-covered Autologous Chondrocyte Implantation” (CACI) or “Matrix-induced Autologous Chondrocyte Implantation” (MACI®).

Matricel is active in research and has a promising pipeline of product developments in different medical fields. Matricel´s quality assurance system is certified according to DIN EN ISO 13485:2003 and according to Therapeutic Goods (Medical Device) Regulations 2002 (Australia) for the development, production, and distribution of biomaterials for applications in medicine, pharmaceutics and biotechnology.